ReviewCalcified tissue international2021
Tumor-Induced Osteomalacia.
Review in Calcified tissue international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Burosumab an emerging therapy in TIO: a local clinical survey and a systematic review with individual patient data analysis.Frontiers in endocrinology · 2026Pooled it
- Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines.BMC medicine · 2025Pooled it
- Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.Endocrine · 2022Pooled it
- Perspective: Vitamin D supplementation prevents rickets and acute respiratory infections when given as daily maintenance but not as intermittent bolus: implications for COVID-19.Clinical medicine (London, England) · 2021Pooled it
- Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.JBMR plus · 2022Trial
- Multimodal Functional Imaging in Tumor-induced Osteomalacia:Molecular imaging and radionuclide therapy · 2026Article
- Late diagnosis of SLC34A3-related hereditary hypophosphatemic osteomalacia following a low-energy proximal humeral 4-part fracture.JBMR plus · 2026Article
- Burden of Disease in Pediatric Tumor-Induced Osteomalacia: A Literature Review.Calcified tissue international · 2026Review
- Article
- Beyond DOTATATE: [European journal of nuclear medicine and molecular imaging · 2026Article
- Phosphaturic Mesenchymal Tumor Masquerading Axial Spondyloarthritis: Diagnostic Challenge and Multidisciplinary Resolution: A Case Report.International journal of rheumatic diseases · 2026Article
- Article
- Global perspectives on the burden and management of hypophosphataemic osteomalacia in adult patients: an International Osteoporosis Foundation (IOF) survey.Archives of osteoporosis · 2026Article
- Article
- Tumor-Induced Osteomalacia Mimicking Metastases on Ga-68 DOTATATE Scan: A Rare Pericytic Variant of Phosphaturic Mesenchymal Tumor.Radiology case reports · 2026Article
- Burosumab in Unidentifiable Tumor-Induced Osteomalacia.Clinical case reports · 2026Article
- Light chain deposition disease masquerading as hypophosphatemic osteomalacia: a case report.Frontiers in medicine · 2026Article
- A nomogram for predicting surgery outcome of tumor-induced osteomalacia: a case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Article
- Disruption of the FGFR1-FGF23-Phosphate Axis and Targeted Therapy in a Murine Model of Osteoglophonic Dysplasia.bioRxiv : the preprint server for biology · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral production of fibroblast growth factor 23 (FGF23). The hallmark biochemical features include hypophosphatemia due to renal phosphate wasting, inappropriately normal or frankly low 1,25-dihydroxy-vitamin D, and inappropriately normal or elevated FGF23. TIO is caused by typically small, slow growing, benign phosphaturic mesenchymal tumors (PMTs) that are located almost anywhere in the body from the skull to the feet, in soft tissue or bone. The recent identification of fusion genes in a significant subset of PMTs has provided important insights into PMT tumorigenesis. Although management of this disease may seem straightforward, considering that complete resection of the tumor leads to its cure, locating these often-tiny tumors is frequently a challenge. For this purpose, a stepwise, systematic approach is required. It starts with thorough medical history and physical examination, followed by functional imaging, and confirmation of identified lesions by anatomical imaging. If the tumor resection is not possible, medical therapy with phosphate and active vitamin D is indicated. Novel therapeutic approaches include image-guided tumor ablation and medical treatment with the anti-FGF23 antibody burosumab or the pan-FGFR tyrosine kinase inhibitor, BGJ398/infigratinib. Great progress has been made in the diagnosis and treatment of TIO, and more is likely to come, turning this challenging, debilitating disease into a gratifying cure for patients and their providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.